You are viewing a version of a model that has been updated. To access the latest version, and a more detailed display please go here.

DDMODEL00000224: Kloft_2006_myelosuppression_docetaxel

  public model
Short description:
This is the myelosuppression model (first published by Friberg et al. 2002) for docetaxel, including covariates identified by Kloft et al., 2006. The variability related to the gamma parameter was set to 0, in contrast to the original publication.
Original code
  • Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
  • Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO
  • Clinical cancer research : an official journal of the American Association for Cancer Research, 9/2006, Volume 12, Issue 18, pages: 5481-5490
  • Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universitaet Berlin, Germany. ckloft@zedat.fu-berlin.de
  • PURPOSE: Cancer chemotherapy, although based on body surface area, often causes unpredictable myelosuppression, especially severe neutropenia. The aim of this study was to evaluate qualitatively and quantitatively the influence of patient-specific characteristics on the neutrophil concentration-time course, to identify patient subgroups, and to compare covariates on system-related pharmacodynamic variable between drugs. EXPERIMENTAL DESIGN: Drug and neutrophil concentration, demographic, and clinical chemistry data of several trials with docetaxel (637 patients), paclitaxel (45 patients), etoposide (71 patients), or topotecan (191 patients) were included in the covariate analysis of a physiology-based pharmacokinetic-pharmacodynamic neutropenia model. Comparisons of covariate relations across drugs were made. RESULTS: A population model incorporating four to five relevant patient factors for each drug to explain variability in the degree and duration of neutropenia has been developed. Sex, previous anticancer therapy, performance status, height, binding partners, or liver enzymes influenced system-related variables and alpha1-acid glycoprotein, albumin, bilirubin, concomitant cytotoxic agents, or administration route changed drug-specific variables. Overall, female and pretreated patients had a lower baseline neutrophil concentration. Across-drug comparison revealed that several covariates (e.g., age) had minor (clinically irrelevant) influences but consistently shifted the pharmacodynamic variable in the same direction. CONCLUSIONS: These mechanistic models, including patient characteristics that influence drug-specific parameters, form the rationale basis for more tailored dosing of individual patients or subgroups to minimize the risk of infection and thus might contribute to a more successful therapy. In addition, nonsignificant or clinically irrelevant relations on system-related parameters suggest that these covariates could be negligible in clinical trails and daily use.
Ida Netterberg
Annotations are correct.
This model is not certified.
  • Model owner: Ida Netterberg
  • Submitted: Oct 13, 2016 9:15:14 AM
  • Last Modified: Oct 13, 2016 3:41:22 PM
Revisions
  • Version: 16 public model Download this version
    • Submitted on: Oct 13, 2016 3:41:22 PM
    • Submitted by: Ida Netterberg
    • With comment: Updated model annotations.
  • Version: 13 public model Download this version
    • Submitted on: Oct 13, 2016 9:15:14 AM
    • Submitted by: Ida Netterberg
    • With comment: Updated model annotations.
 
Help